Treatment of alpha-1-antitrypsin deficiency

By Richard Butt 1 year ago
Project Alpha-1-Antitrypsin Deficiency

Treatment of alpha-1-antitrypsin deficiency – a collaboration with Dr Ravi Mahadeva, University of Cambridge

Dr Mahadeva is a clinical academic at University of Cambridge and Consultant Respiratory Physician, at Addenbrookes Hospital and a current director of the regional centre for management of α1 anti-trypsin deficiency and former chair of the α1 alliance. Apollo and Dr Mahadeva are collaborating to develop novel therapeutic approaches for the treatment of α1 antitrypsin deficiency, an incurable and fatal genetic disorder affecting the liver and lungs. Dr Mahadeva’s research group has discovered a series of novel small molecules that inhibit polymerisation of the Z-form of α1 antitrypsin and subsequently facilitate secretion of functional protein to balance proteolytic pathways in the lung that unchecked lead to development of emphysema and COPD. Apollo and Dr Mahadeva will collaborate to run a drug discovery program aiming to translate these early hits into potential therapeutics.